Boothbay Fund Management LLC Makes New $11.33 Million Investment in ADMA Biologics Inc $ADMA

Boothbay Fund Management LLC acquired a new stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 773,158 shares of the biotechnology company’s stock, valued at approximately $11,334,000. Boothbay Fund Management LLC owned about 0.32% of ADMA Biologics as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada lifted its position in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock worth $1,903,000 after buying an additional 50,801 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in ADMA Biologics during the 1st quarter valued at approximately $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in ADMA Biologics by 59.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock worth $16,201,000 after acquiring an additional 305,064 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in ADMA Biologics by 108.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 143,229 shares of the biotechnology company’s stock worth $2,608,000 after acquiring an additional 74,543 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of ADMA Biologics by 18.1% during the 2nd quarter. Bank of Montreal Can now owns 42,269 shares of the biotechnology company’s stock worth $770,000 after acquiring an additional 6,466 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Steve Elms acquired 7,000 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director directly owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is owned by company insiders.

ADMA Biologics Trading Up 1.1%

Shares of NASDAQ ADMA opened at $15.15 on Friday. ADMA Biologics Inc has a 1-year low of $13.76 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The business’s 50 day moving average is $16.63 and its two-hundred day moving average is $16.71. The stock has a market capitalization of $3.61 billion, a P/E ratio of 25.25 and a beta of 0.51.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.20. The business had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period last year, the company earned $0.46 EPS. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ADMA. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.